Breaking News
11 hours ago
Simantini Singh Deo
Simantini Singh Deo
Chugai Pharmaceutical secures Japanese regulatory approval for Tecentriq® as the first immune inhibitor for unresectable alveolar soft part sarcoma.
Mrudula Kulkarni
Milestone Pharmaceuticals receives USPTO Notice of Allowance, extending U.S. patent protection for CARDAMYST™ (etripamil nasal spray) until 2042.
Simantini Singh Deo
Adial Pharmaceuticals expands its intellectual property with a new patent covering genetic markers for alcohol and opioid addiction treatment.
Simantini Singh Deo
ImmunityBio secures FDA approval to provide an alternative BCG source amid ongoing bladder cancer treatment shortages.
Simantini Singh Deo